Investigational drug · Phase 3
NRX-101
Not approved by FDA. In 1 industry-sponsored Phase 2 or 3 trial that is active or finished in the last two years, most often for Treatment Resistant Depression, Treatment Resistant Depression (TRD).
Phase 3Last checked: Nov 19, 2026Latest source record: Oct 21, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 3
Industry-sponsored trials
Phase 2 and 3 trials
1
1 still active
All registered trials
8
Any phase or sponsor naming "NRX-101"
First trial start
2026
Dec 1, 2026
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "NRX-101", any sponsor or status.
Conditions studied
As listed on its trial records.
- Treatment Resistant Depression
- Treatment Resistant Depression (TRD)
Approved drugs for the same conditions: Depression (major depressive disorder) · Psychiatry
Largest trials
Live from ClinicalTrials.gov: studies naming "NRX-101" as an intervention, largest first.
- A Randomized, Double-Blind Controlled Comparison of NRX-101 vs. Placebo for Adults Being Treated With Robotic Transcranial Magnetic Stimulation for Treatment Resistant Depression: The SPARC-TMS TrialPivotal-lookingRecruiting
NeuroRx, Inc.Industry
NCT07227103 · 240 participants (planned) · Start Dec 1, 2026 · Primary completion Dec 31, 2027
Drug: NRX-101; Oral Placebo · For: Treatment Resistant Depression; Treatment Resistant Depression (TRD)
Sites: Sarasota, Florida; West Palm Beach, Florida; Belmont, Massachusetts
- NRX-101 for Bipolar Depression With Subacute Suicidal IdeationPivotal-lookingCompleted
NeuroRx, Inc.Industry
NCT03395392 · 74 participants · Start May 12, 2022 · Primary completion Feb 28, 2024
Drug: NRX-101; Lurasidone HCl · For: Bipolar Depression; Suicidal Ideation and Behavior
Sites: Culver City, California; Miami Lakes, Florida; Atlanta, Georgia · 14 sites in all
- NRX-101 for Maintenance of Remission From Severe Bipolar Depression in Patients With Suicidal IdeationPivotal-lookingStatus unknown
NeuroRx, Inc.Industry
NCT03396068 · 72 participants (planned) · Start Dec 1, 2019 · Primary completion Dec 31, 2024
Drug: NRX-101; Lurasidone HCl · For: Bipolar Depression; Suicidal Ideation
Sites: Birmingham, Alabama; Hollywood, Florida; Fort Worth, Texas · 4 sites in all
Mclean HospitalAcademic, hospital or other
NCT07785102 · 30 participants (planned) · Start Oct 1, 2026 · Primary completion Dec 31, 2026
Drug: NRX-101 · For: Major Depression
Sites: Belmont, Massachusetts
NeuroRx, Inc.Industry
NCT02974010 · 22 participants · Start Jan 15, 2018 · Primary completion Aug 31, 2018
Drug: NRX-101 Oral Capsule; Lurasidone Oral Capsule and 2 more · For: Bipolar Depression; Suicidal Ideas; Suicidal Ideation and 1 more
Sites: Birmingham, Alabama; Fort Lauderdale, Florida; Charlotte, North Carolina · 4 sites in all
NeuroRx, Inc.Industry
NCT06128213 · 13 participants (planned) · Start Mar 31, 2024 · Primary completion Jun 30, 2024
Drug: NRX101 (a fixed dose combination of D-cycloserine (DCS) and lurasidone HCl (lurasidone)) · For: Urinary Tract Infections; Pyelonephritis
- NRX101 Glx Biomarker Validation StudyPivotal-lookingCompleted
NeuroRx, Inc.Industry
NCT03402152 · 8 participants · Start Nov 1, 2018 · Primary completion Jan 1, 2021
Drug: NRX-101; Lurasidone HCl and 1 more · For: Bipolar Depression; Suicidal Ideation
Sites: New York, New York
- NRX-101 Expanded AccessAvailable
NeuroRx, Inc.Industry
NCT05779267
Drug: NRX-101 · For: Treatment-Resistant Depression
Sites: Belmont, Massachusetts
Newest research
PubMed records naming it or its code names, newest first.
- Emerging pharmacological and neuromodulation interventions for suicidal ideation and behaviour.
Scala M, Magrini E, Leccisotti I, et al. · Eur Neuropsychopharmacol 2026
- Exploring the Potential of NRX-101 for Pediatric Bipolar Depression: A Call for Research and Equity.
Yusuf M, Tariq M, Genovese A · Kans J Med 2026
- Mechanism-Based Polypharmacy as a Repurposing Strategy: The Case of D-Cycloserine and Lurasidone.
Franzen AD, Svendsen JS, Kline CJ, et al. · Clin Transl Sci 2026
- A novel sequential ketamine and D-cycloserine/lurasidone therapy for bipolar depression with acute suicidal ideation.
Takahashi M, Shelton RC · Expert Opin Investig Drugs 2026
- NRX-101 (D-Cycloserine + Lurasidone) Is Active against Drug-Resistant Urinary Pathogens In Vitro.
Sapko MT, Manyak M, Panicucci R, et al. · Antibiotics (Basel) 2024
- NRX-101, a Rapid-Acting Anti-Depressant, Does Not Cause Neurotoxicity Following Ketamine Administration in Preclinical Models.
Jordan W, Sapko MT, Siegel R, et al. · Int J Toxicol 2023
Also in development for Treatment Resistant Depression
- PsilocybinCOMP360Phase 34 trials
COMPASS Pathways · Treatment Resistant Depression, Major Depressive Disorder, Anorexia Nervosa
- PBOPhase 32 trials
SK Life Science, Inc. · Primary Generalized Epilepsy, Treatment Resistant Depression
- BPL-003Phase 22 trials
Beckley Psytech Limited · Treatment Resistant Depression
- NV-5138SPN820Phase 21 trial
Navitor Pharmaceuticals, Inc. · Treatment Resistant Depression
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.